citalopram / Generic mfg. - LARVOL DELTA

Evaluating the Effects of Selective Serotonin Reuptake Inhibitors on Osteogenesis of Periodontal Stem Cells: An In Vitro Study. (PubMed, Int Dent J) - "This study suggests that SSRIs may impair osteogenic differentiation of PDLSCs by suppressing IGF-1 and HGF signaling pathways. These findings provide mechanistic insight into SSRI-induced bone suppression and support the consideration of antidepressant selection in patients requiring bone or periodontal tissue regeneration."

Journal • Preclinical • IGF1

Selective serotonin reuptake inhibitors and glucose metabolism in Alzheimer's disease and related dementias: A systematic review and meta-analysis of brain metabolic and adverse event data. (PubMed, Metabol Open) - "Meta-analysis demonstrated increased gastrointestinal adverse events (risk ratio 2.15, 95 % CI: 1.68-2.76, P-value<0.001, with moderate between-study heterogeneity), with sertraline showing highest rates. These findings support SSRI safety for metabolic outcomes in AD treatment, however longer-term studies with controlled metabolic outcomes are needed to confirm our findings. The observed citalopram weight protection benefit was documented at 30 mg daily, which exceeds recommended dosing limits for elderly patients due to cardiac safety concerns."

Adverse events • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Metabolic Disorders • Psychiatry • Solid Tumor

Comparative risks of opioid overdose in patients on oxycodone initiating selective serotonin reuptake inhibitors. (PubMed, Epidemiology) - "In this study of individuals who added an SSRI to oxycodone, incidence of opioid overdose was low. Patients who initiated sertraline experienced overdose at a slightly lower rate than patients who initiated other SSRIs."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry

Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial. (PubMed, Brain Behav) - "In summary, BTX-A demonstrates efficacy in reducing multiple neuropsychiatric symptoms (such as tension, anxiety, depression, sensitivity, etc.) in PD, with comparable effectiveness to CH, supporting its consideration as an alternative therapeutic option."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Mixed chronic scrotal pain secondary to piriformis scarring treated with PRF: case report. (PubMed, Front Med (Lausanne)) - "To address the stratified intervention needs of mixed pain, we implemented a mechanism-targeted strategy that included ultrasound-guided pulsed radiofrequency (PRF, 42 °C/240 s) at the inferior margin of the piriformis muscle to neuromodulate compressed nerves, perineural ozone/steroid injections to modulate the immunoinflammatory microenvironment, and citalopram to manage central sensitization, with complete pain resolution (VAS 8 → 0) sustained at 3-month follow-up...The therapeutic strategy synergistically addressed all three cascades of mechanisms via C-fiber modulation, reduction of pro-inflammatory cytokines, and reversal of neuroplasticity. This study advances the understanding of CSP etiology beyond idiopathic causes by providing a reproducible mechanism-based precision model for mixed pain syndromes and advocating for multidisciplinary management that integrates interventional techniques, pharmacotherapy, and psychorehabilitation."

Journal • Gynecology • Inflammation • Musculoskeletal Pain • Neuralgia • Pain

The Analgesic Efficacy of Therapies Used for Complex Regional Pain Syndrome: A Systematic Review. (PubMed, Cureus) - "Combinations of local anesthetics and other medications (e.g., lidocaine with citalopram or parecoxib) were especially effective in acute CRPS...RCT evidence supports the use of bisphosphonates, ketamine, and early use of mirror or motor imagery therapies...However, many studies were limited by small size, short follow-up, or methodological flaws. There is an urgent need for large, high-quality, and mechanistically informed RCTs to guide long-term CRPS management."

Journal • Review • Anesthesia • Cardiovascular • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Selective serotonin reuptake inhibitors for amblyopia treatment: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Neurol) - "Three studies used fluoxetine and one study used citalopram as the intervention. Secondary endpoints that capture effects at the level of the retina and the brain would provide knowledge of physiological mechanisms that can improve future therapies. CRD42025633077, https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633077."

Journal • Retrospective data • Review • CNS Disorders • Ophthalmology • Psychiatry • Strabismus

Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems. (PubMed, Drug Saf) - "Statistical signals of DDIs between ADs and potential interacting drugs during pregnancy were identified but not pursued further after case reviews. Uncertainty around medication use and event timing affected the reliability of the outcomes. These findings highlight the need to validate signals using detailed report data and stress the importance of accurate medication reporting."

Adverse events • Journal • CNS Disorders • Diabetes • Gestational Diabetes • Metabolic Disorders

Genetics of SSRI Antidepressant Use and Relationship to Psychiatric and Medical Traits. (PubMed, HGG Adv) - "Using linkage disequilibrium score regression, we detected strong genetic correlations between MVP and the independent UKB cohort for specific SSRIs (fluoxetine rg = 0.82, citalopram rG = 0.89) as well as with headaches (rG = 0.80), major depressive disorder (MDD; rG = 0.77), and spondylosis (rG = 0.84), suggesting stability in trait definition across cohorts. In MVP, SSRI use showed greater locus discovery than MDD (28 vs. 17 loci); comparison to a prior GWAS of anxiety symptoms identified only 5 loci. SSRI use is likely a partial proxy for MDD, while also reflecting distinct features relevant to related disorders such as anxiety."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Pain • Psychiatry • MVP

Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany. (PubMed, Menopause) - "Continuation rates with available treatments for menopausal symptoms in women receiving endocrine therapy for breast cancer treatment/prevention are very low. This indicates a clear unmet need for safe, effective, and well-tolerated treatments in this patient population."

Journal • Breast Cancer • Oncology • Solid Tumor

Survival Outcomes Associated with Antidepressant Use in Glioblastoma: A Cohort Study. (PubMed, Res Sq) - "Amongst SSRIs, only escitalopram (HR 1.33, 95%CI 1.10-1.60) and citalopram (HR 1.31, 95%CI 1.01-1.70) were associated with worse survival. Conclusions SSRIs, SNRIs, serotonin modulators, and atypical antidepressants are associated with worse survival in patients with glioblastoma. Careful selection of antidepressant medication in patients with glioblastoma may be necessary to optimize outcomes."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Cellular interactions and Ion channel signatures in atrial fibrillation remodeling: insights from single-cell analysis and machine learning. (PubMed, Front Cardiovasc Med) - "Finally, drug-targeting analyses suggested that phenytoin sodium-a known antiarrhythmic agent-may exert therapeutic effects by targeting critical EF subtypes in AF. In addition, ionomycin, citalopram, and topiramate exhibit modulatory effects on ion channels, providing new potential treatment avenues. Such drug repurposing represents a rapid and efficient strategy for the discovery of novel AF therapies."

Journal • Atrial Fibrillation • Cardiovascular • AGRN • ANO1 • GRIK2

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions (clinicaltrials.gov) - P1 | N=241 | Completed | Sponsor: Food and Drug Administration (FDA) | Recruiting ➔ Completed

Trial completion • Hepatology • Liver Failure

5-HT as a Diagnostic Tool on the Continuum between Temperament and Disease (WFSBP 2025) - " In a sample of 36 healthy males divided according to an anhedonia questionnaire (Chapman, 1972) into high versus low physical and social anhedonia respectively, specific noradrenergic, dopaminergic and serotonergic psychopharmacological drugs (reboxetine, bromocriptine and citalopram respectively ) were administered in a balanced crossover design at one week intervals. These findings very much resemble the patterns observed in respective psychiatric patients characterised by anhedonia : Low dopamine is evidently related to the overall lack of initiative and motivation in anhedonia, but, specifically low responses to the 5-HT challenge indicate the close relationship between lack of social responsiveness in the normal range and in psychopathy. Results suggest that psychopharmacological challenges by transmitter- specific drugs may serve as diagnostic tools for discriminating subtypes of psychopathological symptoms, and that there is evidence for a continuum between..."

CNS Disorders • Depression • Psychiatry • Schizophrenia

Unveiling Post-SSRI sexual dysfunction: An underrecognized long-term sequela (WFSBP 2025) - "Paroxetine, fluoxetine, and citalopram were the antidepressants with which post-SSRI sexual dysfunction was most commonly observed. No curative treatment has been found to date, and several molecules have been tested, such as buspirone, phosphodiesterase 5 inhibitors, and mirtazapine, with varying degrees of efficacy. Post-SSRI sexual dysfunction is a clinical entity that is still poorly understood by clinicians. Scientific research should be intensified to understand the mechanisms underlying this sexual dysfunction and develop effective treatments."

Late-breaking abstract • CNS Disorders • Psychiatry

Bloody Eosinophils! Upper Gastrointestinal Bleed and Ulceration Unresponsive to PPI in a Young Male With EGID (ACG 2025) - "His medications included PrEP, amlodipine, citalopram, and naproxen...Treatment consisted of fluticasone and high-dose PPIs. This case emphasizes a rare presentation of EGID as UGIB and highlights the clinical necessity of considering EGID in patients with unexplained gastric and duodenal ulcers...Standard treatments include corticosteroids and PPIs, with PPIs notably effective in reducing eosinophil-driven inflammation. This case reinforces the critical importance of early recognition and management of EGID to optimize patient outcomes."

Cardiovascular • Eosinophilia • Eosinophilic Esophagitis • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Peptic Ulcer

A Description of QT-Interval Prolonging Drug Interactions with Fluoroquinolones in Older Women with Uncomplicated Urinary Tract Infections. (PubMed, Can Geriatr J) - "Within 30 days of the FQ dispensation, the most common drug interactions identified were: furosemide (n=702, 20.3% of FQ-drug interactions), citalopram (n=566, 16.4% of FQ-drug interactions), and trazodone (n=461, 13.3% of FQ-drug interactions). An increasing proportion of women dispensed a FQ for uncomplicated UTI experienced a potential QT-interval prolonging drug interaction over the study period. When prescribing FQs to older women, addressing potentially modifiable risk factors for TdP, and monitoring closely, is warranted."

Journal • Infectious Disease • Nephrology

Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents. (PubMed, Pharmaceutics) - "Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Our findings suggest that sex may not affect serum levels of investigated AD and AP in children/adolescents. However, treatment outcome of fluoxetine was associated with sex, with higher probability for a better outcome in female patients diagnosed with mood (affective) disorders."

Journal • ADHD (Impulsive Aggression) • Anorexia • Autism Spectrum Disorder • CNS Disorders • Depression • Genetic Disorders • Psychiatry

Antidepressants stimulate lipoprotein(a) macropinocytosis via serotonin-enhanced cell surface binding. (PubMed, J Lipid Res) - "Extending these experiments to the commonly used serotonin uptake inhibitors (SSRIs) citalopram, sertraline, fluoxetine, and paroxetine, we found that citalopram and paroxetine stimulated Lp(a) uptake. Finally, imipramine and citalopram increased Lp(a) delivery into Rab11 recycling endosomes, but not degradative pathways in the cell. These findings indicate SSRIs such as citalopram and paroxetine may have utility as a potential Lp(a)-lowering therapeutic in people suffering from depression who often have elevated Lp(a) levels and an increased risk of cardiovascular disease."

Journal • Cardiovascular • CNS Disorders • Depression • Dyslipidemia • Psychiatry

Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysis. (PubMed, J Affect Disord) - "Dosing every other day is likely to cause withdrawal effects with the antidepressants examined in this study. These recommendations remain theoretical until further clinical research and empirical validation of our proposed antidepressant tapering regimens."

Journal

Co-prescribing of antidepressants and opioids for non-cancer pain in England, 2010-2019: a descriptive study using CPRD primary care electronic health records. (PubMed, BMC Prim Care) - "There is a substantial group of people co-prescribed opioids and antidepressants in England, including combinations that may be less effective. This information will be useful to help GPs, dispensing professionals, policymakers and others understand how many people in the UK may be at risk of harm from using both types of medicines at the same time, and which groups are particularly affected. Future research should determine whether there are higher risks of adverse events in these co-prescribed groups."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Mood Disorders • Oncology • Pain • Psychiatry

Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation (clinicaltrials.gov) - P4 | N=450 | Completed | Sponsor: Beni-Suef University

New P4 trial • Sexual Disorders

Development and validation of a highly sensitive LC-MS/MS method for quantification of mutagenic N-nitroso desmethyl citalopram in drug formulations (ACS-Fall 2025) - "A multiple reaction monitoring program, MRM, was employed in mass spectrometry, utilising three product ions at m/z 291.1 (quantifier) 138.0, and 263.1 (qualifier) with electrospray ionisation mode. The LC-MS/MS method was validated in accordance with regulatory criteria and deemed appropriate for its intended application."

CNS Disorders • Depression • Psychiatry

Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, J Geriatr Psychiatry Neurol) - "However, SSRI use was associated with an increased risk of falls (RR 1.78; 95% CI 1.15, 2.75; I2 = 0%).ConclusionEscitalopram and citalopram do not significantly reduce agitation in AD but are generally well tolerated. Increased fall risk warrants cautious clinical use.Registration PROSPERO protocol numberCRD420251055237."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Mood Disorders • Psychiatry

Beyond the Imposter: Deciphering Capgras Syndrome and Multidisciplinary Management. (PubMed, Case Rep Psychiatry) - "The management approach involved a personalized treatment plan integrating Lithium sulfate, Citalopram, and Lurasidone, alongside psychosocial interventions. While a partial improvement was observed, the case underscores the complexities of managing CS in the context of LBD, highlighting the need for tailored and multidisciplinary approaches to care. This case contributes to the limited literature on CS in LBD and provides practical insights for clinicians managing similar presentations."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Sleep Disorder